Combination of DYRK2 and TERT Expression Is a Powerful Predictive Marker for Early-stage Breast Cancer Recurrence

Background/Aim: DYRK2 is a dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase induces degradation of telomerase reverse transcriptase (TERT). The expression of both proteins in breast cancer were investigated as predictors of recurrence. Patients and Methods: Two hundred and twenty-one patients with early breast cancer treated at our institute between 2000 and 2009, were included. We used immunohistochemical analyses to measure the expression of DYRK2 and TERT and correlated it with clinicopathological factors and survival. Results: DYRK2 and TERT were positive in 58 (26%) and 86 (39%) of 221 patients, respectively. There was no correlation between DYRK2 and TERT expression and clinicopathological factors. Better disease-free survival was observed in the DYRK2-positive group (p=0.032), and poorer disease-free survival was noted in the TERT-positive group (p=0.023). The DYRK2-positive TERT-negative group exhibited significantly better disease-free survival than the other groups (p=0.006). Conclusion: The combination of DYRK2 and TERT may be a powerful tool to stratify breast cancer patients.

[1]  K. Nabeshima,et al.  Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer , 2014, Tumor Biology.

[2]  F. Couch,et al.  Identification and Validation of an Anthracycline/Cyclophosphamide–Based Chemotherapy Response Assay in Breast Cancer , 2014, Journal of the National Cancer Institute.

[3]  Y. Miki,et al.  DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail. , 2013, Cancer letters.

[4]  Xin Wang,et al.  Dyrk2-associated EDD-DDB1-VprBP E3 Ligase Inhibits Telomerase by TERT Degradation* , 2013, The Journal of Biological Chemistry.

[5]  Y. Miki,et al.  DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells. , 2012, The Journal of clinical investigation.

[6]  Soonmyung Paik,et al.  Gene-expression-based prognostic assays for breast cancer , 2010, Nature Reviews Clinical Oncology.

[7]  K. Kawahara,et al.  Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma. , 2009, The Journal of thoracic and cardiovascular surgery.

[8]  K. Yoshida.  Role for DYRK family kinases on regulation of apoptosis. , 2008, Biochemical pharmacology.

[9]  Y. Miki,et al.  DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. , 2007, Molecular cell.

[10]  W. Hahn,et al.  Inhibition of telomerase limits the growth of human cancer cells , 1999, Nature Medicine.

[11]  H. Joost,et al.  Sequence Characteristics, Subcellular Localization, and Substrate Specificity of DYRK-related Kinases, a Novel Family of Dual Specificity Protein Kinases* , 1998, The Journal of Biological Chemistry.

[12]  A. Sartorelli,et al.  Differentiation of immortal cells inhibits telomerase activity. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[13]  et al.,et al.  The RNA component of human telomerase , 1995, Science.

[14]  J. Steitz,et al.  Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. , 1992, The EMBO journal.

[15]  C. Redmond,et al.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update , 1983, Cancer.